Select your timezone:

Abstracts Session 3

Tuesday May 02, 2023 - 09:20 to 10:30

Room: Grand Georgian

9.6 Single-cell transcriptomic analysis further delineates human CD8+ T regulatory cell subsets

Carole Guillonneau, France

Nantes University


Single-cell transcriptomic analysis further delineates human CD8+ T regulatory cell subsets

Céline Sérazin1, Léa Flippe1, Mathias Streitz2, Désirée-Jacqueline Wendering2, Stephan Schlickeiser2, Hans Dieter Volk2, Ignacio Anegon1, Laurent David1, Séverine Bézie1, Carole Guillonneau1.

1Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France; 2Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany

Introduction: Although described in the 70’s, CD8+ regulatory T cells (Tregs) remains incompletely understood and to date, although several markers are used to define them, they remain inconsistent. The identification of good markers, as it was done for CD4+ Tregs; remains an urgent task and a challenge to advance our understanding.
Methods: Herein, we addressed the heterogeneity within total CD8+ T cells using single cell CITEseq and VDJ T cell receptor sequencing. We included markers used to previously identify Tregs, in particular CD45RC described by our team and others to divide effector (CD45RChigh) and pro-regulatory (CD45RClow/-) CD8+ T cells. 7K non-stimulated CD8+ T lymphocytes, including CD8+CD45RClow/- Tregs and CD8+CD45RChigh T cells of 4 healthy volunteers were analyzed.
Results: These analyses enabled the characterization of the transcriptomic heterogeneity at a single cell level from steady state total CD8+ T cells and allowed definition of regulatory CD8+CD45RClow/- Treg subsets. Functional analysis using cell sorting and suppressive assays highlighted the suppressive potential of the CD8+CD45RClow/-TNFR2+CD29low Tregs subset.
Conclusion: To date, to our knowledge, this is the largest characterization study of human CD8+ Tregs, this huge data resource will help in the current revival of CD8+ Tregs in research, will improve our understanding of T cell heterogeneity and will help translate CD8+ Tregs to the clinic.

Presentations by Carole Guillonneau

Organized by

© 2023 ITS 2023